NEW YORK, June 5, 2012 \/PRNewswire\/ -- Reportlinker.com announces that a new market research report is available in its catalogue: <\/p>\n<\/p>\n
Global Anxiety Disorders Industry <\/p>\n
http:\/\/www.reportlinker.com\/p0552771\/Global-Anxiety-Disorders-Industry.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology<\/a> <\/p>\n<\/p>\n This report analyzes the worldwide markets for Anxiety Disorders in US$ Million. The report provides separate comprehensive analytics for the US, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2009 through 2017. Also, a six-year historic analysis is provided for these markets. The report profiles 63 companies including many key and niche players such as AstraZeneca Plc, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Forest Laboratories, Inc., GlaxoSmithKline Plc, H. Lundbeck A\/S, Mylan, Inc., Neurocrine Biosciences, Inc., Pfizer, Inc., Ratiopharm, Sanofi, UCB SA, Valeant Pharmaceuticals International, and Watson Laboratories, Inc. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based upon search engine sources in the public domain. <\/p>\n<\/p>\n<\/p>\n To order this report: <\/p>\n<\/p>\n Read more: NEW YORK, June 5, 2012 \/PRNewswire\/ -- Reportlinker.com announces that a new market research report is available in its catalogue: Global Anxiety Disorders Industry http:\/\/www.reportlinker.com\/p0552771\/Global-Anxiety-Disorders-Industry.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology<\/a> This report analyzes the worldwide markets for Anxiety Disorders in US$ Million. The report provides separate comprehensive analytics for the US, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2009 through 2017. Continue reading
\nGlobal Anxiety Disorders Industry<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"